Morgan Stanley Intellia Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,576,034 shares of NTLA stock, worth $36.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,576,034

Previous 2,337,709 10.19%

Holding current value

$36.8 Million

Previous $52.3 Million 1.19%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $4.7 Million - $6.52 Million	238,325 Added 10.19%	2,576,034 $52.9 Million
Q2 2024 Oct 17, 2024	SELL	$20.02 - $27.22 $6.15 Million - $8.36 Million	-307,142 Reduced 11.61%	2,337,709 $52.3 Million
Q2 2024 Aug 14, 2024	SELL	$20.02 - $27.22 $6.15 Million - $8.36 Million	-307,142 Reduced 11.61%	2,337,709 $52.3 Million
Q1 2024 Oct 17, 2024	BUY	$23.82 - $32.8 $7.32 Million - $10.1 Million	307,142 Added 13.14%	2,644,851 $72.8 Million
Q1 2024 Aug 16, 2024	BUY	$23.82 - $32.8 $2.38 Million - $3.27 Million	99,829 Added 3.92%	2,644,851 $72.8 Million
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $2.38 Million - $3.27 Million	99,829 Added 3.92%	2,644,851 $72.8 Million
Q4 2023 Aug 16, 2024	BUY	$23.16 - $32.34 $4.8 Million - $6.7 Million	207,313 Added 8.87%	2,545,022 $77.6 Million
Q4 2023 Feb 13, 2024	SELL	$23.16 - $32.34 $12.6 Million - $17.7 Million	-545,919 Reduced 17.66%	2,545,022 $77.6 Million
Q3 2023 Nov 15, 2023	BUY	$31.62 - $45.78 $7.64 Million - $11.1 Million	241,734 Added 8.48%	3,090,941 $97.7 Million
Q2 2023 Aug 14, 2023	BUY	$34.58 - $46.03 $6.7 Million - $8.92 Million	193,724 Added 7.3%	2,849,207 $116 Million
Q1 2023 May 15, 2023	BUY	$33.3 - $44.82 $4.57 Million - $6.16 Million	137,333 Added 5.45%	2,655,483 $99 Million
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $32.8 Million - $61.9 Million	987,599 Added 64.53%	2,518,150 $87.9 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $15.9 Million - $21.1 Million	294,357 Added 23.81%	1,530,551 $85.7 Million
Q2 2022 Oct 27, 2022	SELL	$38.49 - $76.21 $2.26 Million - $4.48 Million	-58,805 Reduced 4.54%	1,236,194 $64 Million
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $2.26 Million - $4.48 Million	-58,805 Reduced 4.54%	1,236,194 $64 Million
Q1 2022 Oct 27, 2022	BUY	$58.27 - $118.99 $3.43 Million - $7 Million	58,805 Added 4.76%	1,294,999 $94.1 Million
Q1 2022 May 13, 2022	SELL	$58.27 - $118.99 $13.3 Million - $27.2 Million	-228,254 Reduced 14.98%	1,294,999 $94.1 Million
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $38 Million - $52.2 Million	377,214 Added 32.91%	1,523,253 $180 Million
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $152 Million - $203 Million	1,146,039 New	1,146,039 $154 Million

Others Institutions Holding NTLA

# of Institutions

313

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.09B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account